Medtronic/$MDT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Medtronic
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Ticker
$MDT
Sector
Primary listing
NYSE
Employees
95,000
Headquarters
Galway, Ireland
Website
Medtronic Metrics
BasicAdvanced
$116B
24.97
$3.62
0.79
$2.82
3.14%
Price and volume
Market cap
$116B
Beta
0.79
52-week high
$99.37
52-week low
$79.29
Average daily volume
6.3M
Dividend rate
$2.82
Financial strength
Current ratio
2.014
Quick ratio
1.248
Long term debt to equity
54.389
Total debt to equity
59.437
Dividend payout ratio (TTM)
77.27%
Interest coverage (TTM)
8.90%
Profitability
EBITDA (TTM)
9,367
Gross margin (TTM)
65.38%
Net profit margin (TTM)
13.63%
Operating margin (TTM)
19.31%
Effective tax rate (TTM)
17.15%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
4.57%
Return on equity (TTM)
9.74%
Valuation
Price to earnings (TTM)
24.967
Price to revenue (TTM)
3.39
Price to book
2.41
Price to tangible book (TTM)
-21.54
Price to free cash flow (TTM)
21.866
Free cash flow yield (TTM)
4.57%
Free cash flow per share (TTM)
4.134
Dividend yield (TTM)
3.12%
Forward dividend yield
3.14%
Growth
Revenue change (TTM)
4.98%
Earnings per share change (TTM)
21.95%
3-year revenue growth (CAGR)
3.25%
10-year revenue growth (CAGR)
3.99%
3-year earnings per share growth (CAGR)
-2.24%
10-year earnings per share growth (CAGR)
5.35%
3-year dividend per share growth (CAGR)
3.02%
10-year dividend per share growth (CAGR)
8.05%
What the Analysts think about Medtronic
Analyst ratings (Buy, Hold, Sell) for Medtronic stock.
Bulls say / Bears say
Medtronic raised its fiscal 2026 adjusted EPS guidance to $5.60–$5.66 from a prior $5.50–$5.60, after estimating tariff costs would be $185 million—less than earlier projections—underscoring operational resilience amid trade uncertainties (Reuters)
Following Elliott Investment Management becoming one of its largest shareholders, Medtronic appointed two independent directors and formed committees to evaluate M&A, R&D investment, and divestitures, strengthening governance and potential value creation (Reuters)
Medtronic’s diabetes unit has delivered six consecutive quarters of double-digit revenue growth, reflecting strong market demand and robust momentum in its innovation pipeline (Reuters)
Medtronic expects U.S. and reciprocal tariffs to add $200 million–$350 million to its cost of goods sold in fiscal 2026, and mitigation efforts may not fully offset this headwind, putting pressure on gross margins (Reuters)
Medtronic’s diabetes division has faced regulatory warnings over quality management and cybersecurity vulnerabilities—challenges that could complicate its planned separation and expose the company to execution and liability risks (Reuters)
Medtronic’s fiscal 2026 EPS guidance of $5.50–$5.60 falls short of the Wall Street consensus of $5.83, reflecting potential growth constraints and market skepticism about its outlook (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
Medtronic Financial Performance
Revenues and expenses
Medtronic Earnings Performance
Company profitability
Medtronic News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Medtronic stock?
Medtronic (MDT) has a market cap of $116B as of November 06, 2025.
What is the P/E ratio for Medtronic stock?
The price to earnings (P/E) ratio for Medtronic (MDT) stock is 24.97 as of November 06, 2025.
Does Medtronic stock pay dividends?
Yes, the Medtronic (MDT) stock pays dividends to shareholders. As of November 06, 2025, the dividend rate is $2.82 and the yield is 3.14%. Medtronic has a payout ratio of 77.27% on a trailing twelve-month basis.
When is the next Medtronic dividend payment date?
The next Medtronic (MDT) dividend payment date is unconfirmed.
What is the beta indicator for Medtronic?
Medtronic (MDT) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.